Cigna (CI) Sees Strong Gains Amid Market Fluctuations

On June 22, 2026, U.S. stock index futures experienced a slight decline, with Nasdaq 100 futures down 0.05%, S&P 500 futures falling 0.17%, and Dow futures dipping 0.05%. In premarket trading, Cigna CI stood out with a notable increase of 8.14%. This performance comes amid ongoing U.S.-Iran negotiations, which have been described as making “progress.”
• Key valuation metric: Cigna’s P/E ratio stands at 11.84x, indicating a relatively low valuation compared to historical averages.
• Insider activity shows significant selling, with $59.4 million in shares sold over the past three months.

The slight decline in U.S. stock index futures reflects a cautious sentiment among traders as they keep an eye on geopolitical developments, particularly the ongoing negotiations between the U.S. and Iran. These discussions could have far-reaching implications for market stability and investor confidence. In this context, Cigna’s strong premarket performance is noteworthy, as it diverges from the broader market trend.

Cigna, officially known as The Cigna Group, operates primarily in the healthcare sector, specifically focusing on healthcare plans. With a market capitalization of approximately $73.9 billion, Cigna provides pharmacy benefit management and health insurance services, serving around 16 million U.S. and 2 million international medical members as of December 2025. The company’s recent growth has been bolstered by its merger with Express Scripts in 2018, which significantly expanded its pharmacy services.

Currently, GF Value™ data is not available for Cigna. However, the company’s P/E ratio of 11.84x indicates that it is trading at a relatively low valuation compared to its historical averages, suggesting potential undervaluation. This low P/E ratio may attract value-oriented investors looking for opportunities in the healthcare sector. For more detailed information, visit the CI stock page.

What Does CI’s GF Score™ Tell Us?

The GF Score™ ranks stocks from 0 to 100 based on five key aspects: Financial Strength, Profitability, Growth, Valuation, and Momentum. Stocks with higher GF Score™ values have been found to generate higher long-term returns (backtested 2006-2021).

Cigna’s GF Score™ of 54 indicates a moderate potential for long-term returns, with balanced strengths in financial strength, profitability, and growth. However, the company faces challenges, particularly in profitability metrics such as declining gross and operating margins. For further insights, visit the CI stock page.

What Are Insiders Doing with CI Stock?

Recent insider activity has shown a significant selling trend, with insiders selling approximately $59.4 million worth of shares over the past three months. This level of insider selling may raise concerns among investors regarding the company’s future prospects, as there have been no insider purchases during this period.

What This Means for Investors

Given the current valuation metrics, moderate GF Score™, and significant insider selling, investors should approach Cigna with caution. While the company demonstrates potential for growth and profitability, the declining financial metrics and insider activity may warrant further investigation before making investment decisions. For the complete analysis, visit the CI stock page. You can also use the GuruFocus Stock Screener to find similar opportunities.

CI’s GF Score™ is 54/100, indicating a moderate potential for long-term returns based on GuruFocus’ proprietary metrics.

CI is currently valued with a P/E ratio of 11.84x, suggesting it is trading at a relatively low valuation compared to historical averages.

What is CI’s P/E ratio compared to historical?

CI’s P/E ratio of 11.84x is close to its 2-year low of 10.78, indicating that the stock may be undervalued relative to its historical performance.…Read more by GuruFocus News